The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
As EE says (7:26), the financial element of the RNS is very small beer. Maybe it’s just a low profile employee leaving the company but I suspect simply a tax-related transaction. Nothing that is going to derail conference/trial updates imo.
That’s a possibility Konar, I agree. Not a reference to actual product / company collaboration but some sort of marketing ploy, to raise and compare the profile of the DNA approach and in fact the company as a whole.
Regardless, imo the inclusion of a reference to BioNTech didn’t happen by accident!
Thanks Chester, I was sat here wondering about the significance of the mention of “follow up data from the BioNTech mRNA vaccine”
Surely has to be Scancell relevant, for them to have included that line.
You mean this?
https://www.abstractsonline.com/pp8/#!/20272/presentation/11402
(You may need to copy paste)
As we know from RNS, Scancell have recently attended Oxford Biologics in London. Worth pointing out I think that there is a sister conference in October, in San Diego and I suspect that might also be a Scancell road trip. Perhaps not in a limousine though 😂
https://oxfordglobal.com/biologics/events/biologics-us-2024
HAGW (Q1 comes to an end one week tomorrow - a recruitment and data published milestone)